FINHUB Insights

PFE · Q2 FY25 · Mar 31 – Jun 29, 2025

Pfizer Q2 FY25: where the revenue came from and where it went

Pfizer Q2 FY25: revenue $14.7B (+10% year over year). Net profit $2.9B. Largest cohort US $8.9B. The whole income statement as a sankey diagram from the SEC filing.

Period
Mar 31 – Jun 29, 2025
Reported
Aug 5, 2025 10-Q
Sankey diagram of Pfizer's income statement for Q2 FY25: revenue of $14.7 billion splits into segments and flows out into costs, taxes and net profit.

Tap the diagram to enlarge · figures in billions of dollars

Revenue$14.7B +10% year over year
Gross profit$10.9B 74% margin
Operating profit$-3.1B -21% margin
Net profit$2.9B 20% margin

The numbers

All figures in billions of U.S. dollars, for Q2 FY25 (period ends Jun 29, 2025).
ItemValueShare of revenueYear over year
Revenue 14.7 100% +10%
US 8.9 61% +13%
International Developed Markets 3.4 23% +7%
International Emerging Markets 2.4 16% +6%
Cost of revenue−3.826%
Gross profit10.974% margin−1pp
SG&A−3.423%−5pp
Other−10.572%+0pp
Operating profit-3.1-21% margin+0pp
Tax−0.1
Net profit2.920%+20pp
Filing on EDGAR More quarters of PFE

Source of the numbers: structured XBRL data from the filing (10-Q). The diagram is generated automatically and checked against EDGAR before release. How we calculate it → About and methodology.

Older quarters